Bone marrow staging for breast cancer: is it better than axillary node dissection?

Area of Science:

• Oncology
• Cancer Biology
• Clinical Pathology

Background:

• Tumor cells in bone marrow are an independent prognostic factor in primary breast cancer.
• Detection of these cells offers better insight into breast cancer biology and systemic spread than lymph node status.
• Axillary lymphadenectomy has significant complications and its survival benefit is debated, necessitating re-evaluation of prognostic factors.

Purpose of the Study:

• To re-evaluate the significance of classic prognostic factors in primary breast cancer in light of modern adjuvant systemic therapies.
• To highlight the value of tumor cell detection in bone marrow as a prognostic indicator.
• To discuss the potential and limitations of bone marrow tumor cell detection methods.

Main Methods:

• Review of existing studies on tumor cell detection in bone marrow for primary breast cancer.
• Comparison of bone marrow tumor cell detection with lymph node status as prognostic factors.
• Discussion of laboratory techniques for tumor cell detection, including antibody selection.

Main Results:

• Tumor cells in bone marrow (cytokeratin-positive or mucin-positive) are a strong independent prognostic factor.
• Bone marrow tumor cell detection better reflects breast cancer's systemic nature than lymph node status.
• Information from the primary tumor (e.g., HER-2/neu) is also crucial for prognosis.

Conclusions:

• Tumor cell detection in bone marrow is a valuable, simple, and repeatable method for assessing prognosis in primary breast cancer.
• The prognostic value of traditional factors like lymph node status needs re-evaluation.
• Standardization of laboratory methods and ideal antibody selection are key challenges for bone marrow tumor cell detection.